Pelin Kilic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pelin Kilic has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Begum Cosar
HücreCELL® Biotechnology Development and Commerce, Inc
4 shared publications - Gunhan Gurman
Department of Hematology, Ankara University Faculty of Medicine, Ankara, Turkey
4 shared publications Ahmet Turan Ince
2 shared publications- Açelya Yilmazer
Ankara University
2 shared publications Begum Cosar
HücreCELL® Biotechnology Development and Commerce, Inc. Ankara Turkey
2 shared publications- Buğrahan Regaip KILINÇ
Kastamonu University, School of Engineering and Architecture, Department of Genetics and Bioengineering, Kastamonu, Turkey; Kastamonu University, School of Engineering and Architecture, Department of Biomedical Engineering, Kastamonu, Turkey
2 shared publications
Latest Publications
- 24 April 2026
- Published by Elsevier in The Journal of Prosthetic Dentistry
- Vol. 136 (2) , e342-e351
Comparative in vitro assessment of zirconia, lithium disilicate, and advanced lithium disilicate ceramics for Ti-base restorations: Surface roughness, cytocompatibility, and quantitative fibroblast adhesion response
- 24 April 2026
- Published by Elsevier in The Journal of Prosthetic Dentistry
- Vol. 136 (2) , e342-e351
Comparative in vitro assessment of zirconia, lithium disilicate, and advanced lithium disilicate ceramics for Ti-base restorations: Surface roughness, cytocompatibility, and quantitative fibroblast adhesion response
- 8 November 2025
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 86, 238-259
The intersection of CAR-T immunotherapy with emerging technologies
- 8 November 2025
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 86, 238-259
The intersection of CAR-T immunotherapy with emerging technologies
- 6 July 2024
- Published by Springer Nature
- p. 265-279
Upstream Process Protocol for MSCs Isolated from Different Human-Based Tissue Origins
This chapter introduces the increasing significance of mesenchymal stromal/stem cell (MSC) production in regenerative medicine and cellular therapeutics, outlines the growing interest in MSCs for various medical applications, and highlights their potential in advanced therapy medicinal products (ATMPs) and the advancements in cell culture technologies that have facilitated large-scale MSC production under Good Manufacturing Practices (GMP), ensuring safety and efficacy. This chapter describes an optimized upstream protocol for laboratory-scale MSC production from different tissue sources. This protocol, conducted in flasks, controls critical parameters and lays the foundation for downstream processing to generate ATMPs. This comprehensive approach underscores the potential of MSCs in clinical applications and the importance of tailored production processes.
- 6 July 2024
- Published by Springer Nature
- p. 265-279
Upstream Process Protocol for MSCs Isolated from Different Human-Based Tissue Origins
This chapter introduces the increasing significance of mesenchymal stromal/stem cell (MSC) production in regenerative medicine and cellular therapeutics, outlines the growing interest in MSCs for various medical applications, and highlights their potential in advanced therapy medicinal products (ATMPs) and the advancements in cell culture technologies that have facilitated large-scale MSC production under Good Manufacturing Practices (GMP), ensuring safety and efficacy. This chapter describes an optimized upstream protocol for laboratory-scale MSC production from different tissue sources. This protocol, conducted in flasks, controls critical parameters and lays the foundation for downstream processing to generate ATMPs. This comprehensive approach underscores the potential of MSCs in clinical applications and the importance of tailored production processes.
- Open Access
- 30 April 2024
- Published by Wiley in Electrophoresis
- Vol. 45 (17-18) , 1606-1617
Residual protein analysis by SDS–PAGE in clinically manufactured BM‐MSC products
Residual substances that are considered hazardous to the recipient must be removed from final cellular therapeutic products manufactured for clinical purposes. In doing so, quality rules determined by competent authorities (CAs) for the clinical use of tissue‐ and cell‐based products can be met. In our study, we carried out residual substance analyses, and purity determination studies of trypsin and trypsin inhibitor in clinically manufactured bone marrow‐derived mesenchymal stromal/stem cell products, using the sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) method. Despite being a semiquantitative method, SDS–PAGE has several benefits over other methods for protein analysis, such as simplicity, convenience of use, and affordability. Due to its convenience and adaptability, SDS–PAGE is still a commonly used method in many laboratories, despite its limits in dynamic range and quantitative precision. Our goal in this work was to show that SDS–PAGE may be used effectively for protein measurement, especially where practicality and affordability are the major factors. The results of our study suggest a validated method to guide tissue and cell manufacturing sites for making use of an agreeable, accessible, and cost‐effective method for residual substance analyses in clinically manufactured cellular therapies.
- 30 April 2024
- Published by Wiley in Electrophoresis
- Vol. 45 (17-18) , 1606-1617
Open AccessResidual protein analysis by SDS–PAGE in clinically manufactured BM‐MSC products
Residual substances that are considered hazardous to the recipient must be removed from final cellular therapeutic products manufactured for clinical purposes. In doing so, quality rules determined by competent authorities (CAs) for the clinical use of tissue‐ and cell‐based products can be met. In our study, we carried out residual substance analyses, and purity determination studies of trypsin and trypsin inhibitor in clinically manufactured bone marrow‐derived mesenchymal stromal/stem cell products, using the sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) method. Despite being a semiquantitative method, SDS–PAGE has several benefits over other methods for protein analysis, such as simplicity, convenience of use, and affordability. Due to its convenience and adaptability, SDS–PAGE is still a commonly used method in many laboratories, despite its limits in dynamic range and quantitative precision. Our goal in this work was to show that SDS–PAGE may be used effectively for protein measurement, especially where practicality and affordability are the major factors. The results of our study suggest a validated method to guide tissue and cell manufacturing sites for making use of an agreeable, accessible, and cost‐effective method for residual substance analyses in clinically manufactured cellular therapies.
- 1 September 2023
- Published by Springer Nature
- p. 193-205
An Optimized Protocol for piggyBac-Induced iPSC Generation from hPBMCs by Automatic Electroporation
Thanks to the Yamanaka transcription factors, pluripotency is recovered in the cell culture dish during in vitro cell reprogramming. Induced pluripotent stem cells (iPSCs) have been introduced to the scientific world as a source of disease models, which are predominantly used in drug discovery and monitoring disease pathophysiology, and as a source of master cell lines for developing cellular therapies. Successfully attaining iPSCs requires careful optimization of many factors, including selection of the transfection method and the appropriate transfection agents; culturing conditions before and after transfection; recovery conditions after transfection, freezing, and thawing; storage conditions; and the choice of cost-effective cell and colony characterization and molecular verification steps. In our optimized procedure, we describe the isolation of peripheral blood mononuclear cells (PBMCs) after blood harvest and their efficient reprogramming into iPSCs using automated electroporator, with piggyBac. Key words Cryopreservation Electroporation Induced pluripotent stem cells (iPSCs) Passaging Peripheral blood mononuclear cells (PBMCs) piggyBac Transfection
- 1 September 2023
- Published by Springer Nature
- p. 193-205
An Optimized Protocol for piggyBac-Induced iPSC Generation from hPBMCs by Automatic Electroporation
Thanks to the Yamanaka transcription factors, pluripotency is recovered in the cell culture dish during in vitro cell reprogramming. Induced pluripotent stem cells (iPSCs) have been introduced to the scientific world as a source of disease models, which are predominantly used in drug discovery and monitoring disease pathophysiology, and as a source of master cell lines for developing cellular therapies. Successfully attaining iPSCs requires careful optimization of many factors, including selection of the transfection method and the appropriate transfection agents; culturing conditions before and after transfection; recovery conditions after transfection, freezing, and thawing; storage conditions; and the choice of cost-effective cell and colony characterization and molecular verification steps. In our optimized procedure, we describe the isolation of peripheral blood mononuclear cells (PBMCs) after blood harvest and their efficient reprogramming into iPSCs using automated electroporator, with piggyBac. Key words Cryopreservation Electroporation Induced pluripotent stem cells (iPSCs) Passaging Peripheral blood mononuclear cells (PBMCs) piggyBac Transfection
- Top Cited Papers
- 1 February 2022
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 63, 10-22
SARS-CoV-2 Mutations and their Viral Variants
- 1 February 2022
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 63, 10-22
Top Cited PapersSARS-CoV-2 Mutations and their Viral Variants
- Open Access
- 30 August 2021
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF BIOLOGY
- Vol. 45 (SI-1) , 404-424
Host variations in SARS-CoV-2 infection
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the zoonotic pathogen that causes the "Coronavirus Disease of 2019 (COVID-19)", and COVID-19 itself is yet to be thoroughly understood. Both the disease as well as the mechanisms by which the host interacts with the SARS-CoV-2 have not been fully enlightened. The epidemiological factors -e.g. age, sex, race-, the polymorphisms of the host proteins, the blood types and individual differences have all been in discussions about affecting the progression and the course of COVID-19 both individually and collectively, as their effects are mostly interwoven. We focused mainly on the effect of polymorphic variants of the host proteins that have been shown to take part in and/or affect the pathogenesis of COVID-19. Additionally, how the procedures of diagnosing and treating COVID-19 are affected by these variants and what possible changes can be implemented are the other questions, which are sought to be answered.
- 30 August 2021
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF BIOLOGY
- Vol. 45 (SI-1) , 404-424
Open AccessHost variations in SARS-CoV-2 infection
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the zoonotic pathogen that causes the "Coronavirus Disease of 2019 (COVID-19)", and COVID-19 itself is yet to be thoroughly understood. Both the disease as well as the mechanisms by which the host interacts with the SARS-CoV-2 have not been fully enlightened. The epidemiological factors -e.g. age, sex, race-, the polymorphisms of the host proteins, the blood types and individual differences have all been in discussions about affecting the progression and the course of COVID-19 both individually and collectively, as their effects are mostly interwoven. We focused mainly on the effect of polymorphic variants of the host proteins that have been shown to take part in and/or affect the pathogenesis of COVID-19. Additionally, how the procedures of diagnosing and treating COVID-19 are affected by these variants and what possible changes can be implemented are the other questions, which are sought to be answered.
- 5 February 2021
- Published by Springer Nature
- p. 263-279
Quality Management Systems (QMSs) of Human-Based Tissue and Cell Product Manufacturing Facilities
In the broadest sense, a quality management system (QMS) runs by continuous interaction of elements based on processes, procedures, policies, guidelines, and resources that are compiled to guide an organization under the scope of its operational mission, vision, and objectives. QMSs in the biopharmaceutical sector defines a written and applied set of rules which aids in improvement of the quality of biopharmaceutical process engineering, while primarily assuring human tissue- and cell-based starting material and end product safety and minimizing the risk of human medicinal product recall, in the most cost-effective ways possible. This chapter aims to outline the crucial position of a QMS under the scope of good practices (GxPs) in the biopharmaceutical industry, as regards human tissue- and cell-based products.
- 5 February 2021
- Published by Springer Nature
- p. 263-279
Quality Management Systems (QMSs) of Human-Based Tissue and Cell Product Manufacturing Facilities
In the broadest sense, a quality management system (QMS) runs by continuous interaction of elements based on processes, procedures, policies, guidelines, and resources that are compiled to guide an organization under the scope of its operational mission, vision, and objectives. QMSs in the biopharmaceutical sector defines a written and applied set of rules which aids in improvement of the quality of biopharmaceutical process engineering, while primarily assuring human tissue- and cell-based starting material and end product safety and minimizing the risk of human medicinal product recall, in the most cost-effective ways possible. This chapter aims to outline the crucial position of a QMS under the scope of good practices (GxPs) in the biopharmaceutical industry, as regards human tissue- and cell-based products.
- 15 July 2020
- Published by Springer Nature in Cell and Tissue Banking
- Vol. 21 (4) , 585-596
Understanding factors affecting human chondrocyte culturing: an experimental study
Over the years, surgical strategies have been developed in hope of full regeneration of the injured cartilage. In our study, we aimed to develop an optimized chondrocyte culture isolation technique as an active ingredient of a standardized autologous chondrocte implantation product, which is able to maintain the phenotype along with the molecular features of the cartilage. We compared different enzymes, which suggested optimal performance with collagenase type II at 5 mg/ml concentration. Thereafter, we observed that COL2 and GAG expression is substantially reduced with passaging. There was a need to omit passaging to reach the optimal isolation method. We then tested various growth factors and media in order to maintain the natural character of chondrocytes. Our study also suggested the highest COL2 and GAG expressions with the highest recovery in the presence of Advanced DMEM. Autologous chondrocyte implantation manufacturing approval was recently received from the national competent authority, making it possible to utilize the process engineering protocol developed with this study at our Tissue and Cell Manufacturing Center as a part of the autologous chondrocyte implantation manufacturing standard operation procedure (SOP).
- 15 July 2020
- Published by Springer Nature in Cell and Tissue Banking
- Vol. 21 (4) , 585-596
Understanding factors affecting human chondrocyte culturing: an experimental study
Over the years, surgical strategies have been developed in hope of full regeneration of the injured cartilage. In our study, we aimed to develop an optimized chondrocyte culture isolation technique as an active ingredient of a standardized autologous chondrocte implantation product, which is able to maintain the phenotype along with the molecular features of the cartilage. We compared different enzymes, which suggested optimal performance with collagenase type II at 5 mg/ml concentration. Thereafter, we observed that COL2 and GAG expression is substantially reduced with passaging. There was a need to omit passaging to reach the optimal isolation method. We then tested various growth factors and media in order to maintain the natural character of chondrocytes. Our study also suggested the highest COL2 and GAG expressions with the highest recovery in the presence of Advanced DMEM. Autologous chondrocyte implantation manufacturing approval was recently received from the national competent authority, making it possible to utilize the process engineering protocol developed with this study at our Tissue and Cell Manufacturing Center as a part of the autologous chondrocyte implantation manufacturing standard operation procedure (SOP).